Daewoong Pharmaceutical Partners with LG Chem to Market Diabetes Combination Drug 'Jemidapa'

Daewoong Pharmaceutical announced on the 18th that it has signed a joint sales agreement with LG Chem for the diabetes treatment drug 'Jemidapa' and started sales this month. With this, Daewoong Pharmaceutical will jointly sell the entire Jemiglo family lineup of LG Chem, including 'Jemiglo', 'Jemimet', and 'Jemidapa'.

LG Chem's diabetes treatment combination drug 'Zemidapa'
[Photo by LG Chem]

Jemidapa is a two-drug fixed-dose combination new drug that combines LG Chem's Jemiglo (active ingredient: gemigliptin), the No. 1 product in the dipeptidyl peptidase (DPP)-4 inhibitor class, with the sodium-glucose co-transporter (SGLT)-2 inhibitor 'dapagliflozin'. Jemidapa is the only combination drug that combines these two ingredients. By using the DPP-4 inhibitor, which promotes insulin production and breaks down sugar, together with the SGLT-2 inhibitor, which expels sugar outside the body, complementary treatment for diabetes symptoms is possible.

Daewoong Pharmaceutical previously elevated Jemiglo to the No. 1 position in the domestic diabetes treatment market through joint sales with LG Chem. Building on the successful know-how from this cooperation, the two companies will introduce Jemidapa this year and begin joint promotions targeting hospitals and clinics nationwide. The two companies plan to further strengthen their partnership to firmly secure the No. 1 position in the domestic diabetes treatment market, valued at 1.43 trillion KRW, and continue to lead the market.

Park Eun-kyung, Head of the Prescription Drug (ETC) Marketing Division at Daewoong Pharmaceutical, said, "We are very pleased to continue our partnership with LG Chem," adding, "Since both companies possess domestic new drugs for diabetes and are leading the market, rapid expansion of market share is expected through joint sales."

Hwang In-chul, Head of LG Chem's Primary Care Business Division, also stated, "We will strengthen our partnership in the diabetes field to solidify our overwhelming No. 1 position in the domestic market," and added, "We will continue to enhance the unique competitiveness of the Jemiglo family through ongoing research and development (R&D) investment."

This content was produced with the assistance of AI translation services.